CHIESI FARMACEUTICI S.P.A.
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 18
- Registration Number
- NCT01343745
- Locations
- 🇬🇧
Respiratory Clinical Trials - Heart Lung Centre - Queen Anne Street Medical Centre, London, United Kingdom
Foster With or Without Charcoal Block or Aerochamber Plus
- Conditions
- Interventions
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 13
- Registration Number
- NCT01280175
- Locations
- 🇨🇭
CROSS Research SA, Arzo, Via F.A. Giorgioli, 14, Switzerland
A Study in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 373
- Registration Number
- NCT01245569
- Locations
- 🇮🇹
Policlinico Umberto I - VIII Padiglione, Rome, Italy
A Study Comparing the Pharmacokinetic, Pharmacodynamic and Safety of CHF 1535 (Fixed Combination of Beclomethasone + Formoterol) Administered Via the NEXT DPI, Versus the Free Combination of Licenced Beclomethasone DPI and Formoterol DPI in Asthmatic Adolescent and Adult Patients.
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 57
- Registration Number
- NCT01191424
- Locations
- 🇩🇰
Copenhagen University Hospital, Copenhagen, Denmark
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 28
- Registration Number
- NCT01176747
- Locations
- 🇩🇪
Inamed Research GmbH & Co. KG, Gauting, Germany
Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 20
- Registration Number
- NCT01176851
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration
- Conditions
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2021-10-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 65
- Registration Number
- NCT01176903
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer
- Conditions
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 25
- Registration Number
- NCT01116089
- Locations
- 🇲🇩
SMSI Institude of Cardiology, Chisinau, Moldova, Republic of
🇨🇿University Hospital Brno Bohunice, Brno, Czechia
🇸🇰University Hospital of L. Pasteur, Pneumonology Department, Kosice, Slovakia
A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
- Conditions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 209
- Registration Number
- NCT01111383
- Locations
- 🇵🇱
I Oddzial Chorob Dzieciecych, Wojewodzki Specjalistyczny Szpital Dzieciecy, Kielce, Poland
🇵🇱Dzieciecy Szpital Kliniczny Akademii Medycznej, Klinika Chorob Pluc I Reumatologii, Lublin, Poland
🇵🇱Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj, Rabka Zdroj, Poland
Prospective Study on Asthma Control
- Conditions
- First Posted Date
- 2010-04-26
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 2875
- Registration Number
- NCT01110460